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past, present and future directions of an international model
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JA Snowden1,2, E McGrath3, RF Duarte4, R Saccardi5, K Orchard6, N Worel7, J Kuball8, C Chabannon9 and M Mohty10
Blood and marrow transplantation (BMT) is a complex and evolving medical speciality that makes substantial demands on healthcare
resources. To meet a professional responsibility to both patients and public health services, the European Society for Blood and
Marrow Transplantation (EBMT) initiated and developed the Joint Accreditation Committee of the International Society for Cellular
Therapy and EBMT—better known by the acronym, JACIE. Since its inception, JACIE has performed over 530 voluntary accreditation
inspections (62% ﬁrst time; 38% reaccreditation) in 25 countries, representing 40% of transplant centres in Europe. As well as
widespread professional acceptance, JACIE has become incorporated into the regulatory framework for delivery of BMT and other
haematopoietic cellular therapies in several countries. In recent years, JACIE has been validated using the EBMT registry as an effective
means of quality improvement with a substantial positive impact on survival outcomes. Future directions include development of
Europe-wide risk-adjusted outcome benchmarking through the EBMT registry and further extension beyond Europe, including goals to
faciliate access for BMT programmes in in low- and middle-income economies (LMIEs) via a ‘ﬁrst-step’ process.
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INTRODUCTION
The impact of quality standards is now felt in many areas of
clinical and laboratory practice, along with a substantial bureau-
cracy on top of clinical work. However, measurable beneﬁts on
patient outcomes remain uncertain in many areas.1
High-risk procedural specialities (such as cardiac surgery) lend
themselves to the introduction of quality measurement and
reporting initiatives because serious procedural morbidities and
mortality are an intrinsic part of delivering such complex
treatments to patients with generally poor prognosis, which can
relatively easily be quantiﬁed. Potentially, a relatively small
specialised clinical community makes it easier to organise agreed
quality standards and collect standardised activity and
outcome data.
Blood and marrow transplantation (BMT) is a complex multi-
disciplinary medical speciality with patients commonly being
consented for levels of treatment-related mortality risk as high as
40%,2 as well as signiﬁcant long-term post-transplant morbidity,
balanced against the adverse prognosis of the many diseases for
which BMT is indicated.3 Procedure-related risks are highest in the
ﬁrst year, but frequently persist for several years following
transplant, reﬂecting the profound immune suppression and
other chronic complications associated with the procedure. Access
to high-quality specialist care, within reasonable travelling times, is
associated with improved long-term outcomes.4–7
The use of living donors, sourced from both family members
and international unrelated bone marrow donor registries, adds
another important and almost unique dimension to the speciality,
requiring robust systems to ensure quality as well as compliance
with legal and regulatory frameworks. Despite such checks and
balances, therapeutic activity derived from living cells is suscep-
tible to intrinsic biological variability that can never be completely
corrected by manufacturing processes or batch validation in
contrast to ‘traditional’ pharmaceutical products.
The aim of this article is to summarise the evolution and current
status of JACIE; the Joint Accreditation Committee of ISCT
(International Society for Cellular Therapy; www.celltherapysoci
ety.org) and EBMT (European Group for Blood & Marrow
Transplantation; www.ebmt.org) in relation to its international
acceptance and validation as an effective means of quality
improvement with an impact on survival outcomes. Future
directions include the development of risk-adjusted outcome
benchmarking and the extension of the concept to transplant
centres in low- and middle-income economies (LMIEs) via a ‘ﬁrst-
step’ process.
QUALITY IN BMT: AN INTERNATIONAL MODEL
Almost 20 years ago, European leaders in BMT established JACIE.
The goal was an internationally harmonised accreditation system
based on agreed quality standards and implemented by teams of
voluntary inspectors.8 The basic concept was adapted from an
earlier initiative in the United States—the Foundation for the
Accreditation of Cellular Therapy (FACT; www.factwebsite.org/)—
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and since then JACIE and FACT have actively collaborated
on maintaining a single set of international quality standards
(www.jacie.org/standards).
Standards were established in the three main areas of
transplant practice as follows: (1) patient care and facilities during
the transplant period; (2) donor care during collection of blood
and marrow cells; and (3) laboratory processing, storage and
delivery of the blood and marrow cells. In each transplant centre,
in-house quality management systems underpin the implementa-
tion of the standards and integrate the members of clinical and
scientiﬁc teams involved with the delivery of the service. Accurate
data collection is key, including centralised reporting of patient
outcome. In some countries, individual centre results of national
outcome analyses, such as those from the British Society for Blood
and Marrow Transplantation,9 are made available to external
review.
BMT is a rapidly evolving ﬁeld, and now involves not only blood
and marrow stem cells but many other cellular, immune and
cytotoxic therapies, and increasingly overlaps with other areas of
‘regenerative medicine’. The FACT–JACIE standards have moved
with the times, with revisions produced every 3 years. Currently,
the standards are in their 6th edition, with preparation of the 7th
edition underway with publication expected in early 2018.
Development of each edition is based on a transparent, structured
programme of work, involving international experts and public
consultation. The standards are openly available at no cost from
the FACT and JACIE web sites. Importantly, ﬂexibility is built in to
allow for national regulatory requirements.
ADOPTION ACROSS EUROPE
Since its outset, JACIE was set up as a European network
coordinated from a central ofﬁce in Barcelona, Spain. Other than
on-site inspection visits, almost all administrative aspects of the
programme are delivered remotely using e-mail, internet tools
and teleconferencing. JACIE is constituted as a committee of the
EBMT with two representatives of the ISCT. Financially, JACIE is run
on a not-for-proﬁt basis, resourced almost entirely by application
fees. The EBMT contributes administrative support.
Currently, there are ~ 260 active trained inspectors. The
operational language of JACIE is English, although inspections
are usually conducted in local languages. Applicant centres are
required to translate a selection of their local documents into
English only when it is not possible to assign a team familiar with
the centre’s working language. Inspection reports are drafted in
English by the inspection team, which are reviewed centrally by
experienced BMT professionals working with the JACIE Ofﬁce.
Inspections are overseen by an accreditation committee, and
there is a deﬁned pathway for appeal in the event of
disagreement. However, this has rarely been invoked, with just
one case brought formally to appeal in the last 10 years. The
Barcelona ofﬁce organises training events on a regular basis,
including at the EBMT Annual meeting, and provides constructive
advice during centre preparation. As a result, only 4 of 647
applications have been rejected, mainly because activity fell below
the thresholds established in the standards. Surveys have
consistently shown high levels of satisfaction with the process—
in 2016, of 46 centres completing a satisfaction survey following
the preparation phase and inspection, 78% were very satisﬁed,
22% were satisﬁed and 0% dissatisﬁed.
Since its inception, JACIE has performed over 530 accreditation
inspections (62% ﬁrst time; 38% reaccreditation) in 25 countries,
representing ~ 40% of transplant centres in Europe. Although
most transplant programmes are in Northern, Southern and
Western Europe, centres from Central Europe, the Middle East,
Asia and South Africa have also requested accreditation. The
process is based on the FACT–JACIE standards and compliance is
uniformly checked for all countries, although national regulations
will always prevail over standards where a conﬂict arises. Thus, all
transplant programmes are expected to meet the same standards,
regardless of location. See Figure 1.
JACIE accreditation is now mandatory in a number of European
countries in relation to regulation of BMT practice, public health
commissioning or private insurance reimbursement (for example,
Belgium, Croatia, France, Italy, Switzerland, The Netherlands
and United Kingdom) and national treatment guidelines
(www.jacie.org/about/national-regulations). In addition, some
clinical trials have included JACIE accreditation among their
criteria for entry and this is likely to be increasingly requested for
clinical trials of innovative cellular therapies, such as immune
effector cells, where high-level standards for product tracking and
clinical monitoring after administration are required.
In several European countries, including The Netherlands, the
United Kingdom and Switzerland, 100% of all BMT centres
(Centres reporting data to the EBMT Annual Activity Survey
2014;10 www.ebmt.org/Contents/Research/TransplantActivitySur
vey/Results/Pages/Results.aspx) performing allogeneic transplan-
tation are accredited by JACIE. Uptake has also been high in
Belgium, Sweden and Italy, but relatively low (o45%) in well-
resourced countries such as Spain and Austria. Centres in France
and Germany are intermediate in their uptake. Further analysis is
warranted in this area to identify barriers that impede engage-
ment or other reasons for lack of interest among centres. In recent
years, evolving interest has been followed by successful accred-
itation in Central Europe, Turkey, Saudi Arabia, Lebanon, South
Africa and Singapore. See Figure 2.
CLINICAL BENEFITS OF JACIE QUALITY STANDARDS
Has any of this activity made any impact on clinical outcomes?—a
crucial question given the effort and resources required to
establish and maintain the required standards in each transplant
centre. Unusually for the ﬁelds of ‘Quality in Healthcare’ and
‘Accreditation Science’, evidence does exist for BMT. Studies using
European BMT registry data have correlated roll-out of accredita-
tion with improvements in patient survival and reduction in
procedural mortality.4,5 The magnitude of improvement achieved
by the relatively simple internal adoption of quality systems,
combined with external inspection and accreditation, was as great
as many other recent and more highly publicised scientiﬁc or
pharmacological advances in the ﬁeld. Evidence relating clinical
trials participation and FACT accreditation in the United States also
indicated a positive impact, although with mixed ﬁndings.11
Implementation of the standards and accreditation are also
strongly associated with closer alignment with international
consensus donor care recommendations for related donors
compared with centres without accreditation.12–15 For these
reasons, JACIE may be regarded as a prototypical development
in clinical medicine, with the potential to be extended to other
medical specialties.
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Figure 1. Growth in ﬁrst-time accredited blood and marrow
transplant centres across Europe and elsewhere 2001–2016.
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An additional advantage of the FACT–JACIE standards is that
they bring together clinicians, and personnel from the collection
and processing facilities, in pursuance of a common goal; this is
rarely seen in the context of authorisation/accreditation by other
national or international competent authorities, where the scope
is most often restricted to a narrower and more technical ﬁeld of
activity.16
BENEFITS OF INTERNATIONAL VERSUS NATIONAL QUALITY
STANDARDS
Internationally scoped quality systems such as JACIE may offer
advantages over locally or nationally delivered schemes. In
complex high-risk specialities such as BMT where overall caseload
is relatively small and in some countries where centres of practice
may be few in number and/or cover large geographic areas, it may
be challenging to develop, resource and implement robust
national quality systems. The improvement in patient outcomes
with JACIE accreditation would have been statistically difﬁcult to
prove in any national system, or at least would have taken
signiﬁcantly longer, even in relatively populous countries.
From a practical point of view, BMT clinicians are highly mobile,
frequently training and working in more than one country during
their career. A common international quality ‘language’ has been
effectively transferred across national borders and health services,
reducing the effect of individual experiential bias or ‘agenda’ and
inﬂuence of dominant local ﬁnancial, clinical or academic conﬂicts
of interest. Moreover, access to a large pool of trained volunteer
inspectors across Europe, with independent oversight and deﬁned
pathways for appeal via governing bodies in the event of
disagreement, can also avoid compromising objectivity through
local familiarity.
POTENTIAL DISADVANTAGES OF JACIE
Many facets of healthcare are already subject to regulation. In
particular, the ﬁeld of transplantation has been the focus of
numerous national and European directives, and transposition to
national laws has resulted in regular inspection visits from
competent authorities. Any new scheme may potentially add a
further layer of bureaucracy and little additional clinical value. In
the case of JACIE, this impact has been countered by ensuring that
the standards are frequently revised and consistent with current
trans-national regulations, including European Union Directives.
Overlap between regulations and accreditation means that they
complement rather than conﬂict with each other reducing
‘inspection overload’. A facility that complies with the European
Union Tissue and Cells Directive for instance will meet most or all
of the JACIE standards. In any case, any voluntary international
accreditation scheme must cede precedence to local regulatory or
legal requirements.
English is the lingua franca of science and medicine, and this is
reﬂected in the JACIE accreditation scheme with practically all
standards and guidance documentation being in English. An
assumption is made that physicians and senior scientists in most
countries have sufﬁcient English to interpret the requirements of
the standards. On the other hand, this may not be the case among
other relevant groups. For instance, many healthcare profes-
sionals, such as nurses, or patients and their families (including
donors in the case of allogeneic transplantation) may not have
sufﬁcient proﬁciency in English to comprehend the detail of the
standards. To widen understanding of the requirements, transla-
tion of the text into other languages, for example, Spanish, French
and Turkish has been sporadically undertaken by third parties, for
example, national haematology societies and has been accepted
by FACT and JACIE with the proviso that the original English will
always be the reference text. However, translation carries the risk
Figure 2. Take-up of accreditation by centres reporting transplants (auto and/or allo) performed in 2014 to the EBMT Activity Survey.
Percentage represents number of centres that have applied at least once to JACIE.
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of altered, incomplete or delayed ﬁdelity to the evolving original
English versions and updating translated versions presents such
practical challenges and costs that the JACIE Ofﬁce decided soon
after its establishment not to take on this task. In any case, most
countries have a National Representative serving as local contact
to help address any issues arising from a local interpretation of the
standard.
BENCHMARKING OF SURVIVAL OUTCOMES
In some other specialities, the use of disease registries enables
professionals to engage in continuous learning and share best
clinical practices, leading to improved quality care.17
The EBMT registry was established in 1974 as a cornerstone of
the society and by 2016 had grown to over half a million
registered transplants. Evolution of JACIE alongside the registry
has enabled a reciprocal relationship to develop. First, JACIE has
always required that the inspection team verify that data collected
by each applicant centre matches that stipulated by the EBMT
registry (that is, Minimal Essential Data forms) or equivalent.
Second, the EBMT megaﬁle has been used to validate the beneﬁts
of the roll-out of JACIE in terms of survival outcome beneﬁts.
Third, the EBMT registry represents a resource for outcome
benchmarking.
The EBMT has embarked on developing a benchmarking system
for its member centres, based on its two major integral elements:
the sizable registry and JACIE accreditation. The North American
counterpart of the EBMT, the Center for International Blood and
Marrow Transplant Research, has for several years performed
centre benchmarking in allogeneic BMT via the Stem Cell
Therapeutic Outcomes Database scheme (www.cibmtr.org/
About/WhatWeDo/SCTOD/Pages/index.aspx) although in that
case, Center for International Blood and Marrow Transplant
Research is distinct from FACT.
Although scientiﬁcally and statistically challenging, benchmark-
ing has the potential to assure quality of centres performing
equivalent treatments. Although presenting a major opportunity
for quality improvement, comparing outcomes of clinical practice
will inevitably be a sensitive issue. Risk-adaption will be essential
given that transplant programmes may be shaped by historical
events, staff expertise, referral patterns, case-mix and ﬁnancial
restraints rather than exclusively scientiﬁc or outcome-driven
factors. Notwithstanding, there is the opportunity for the BMT
community to learn from both the high and low achievers, as well
as providing information to other stakeholders, such as public
health commisioners, healthcare insurers, health technology
assessment bodies and other regulators.
AN UNMET NEED: QUALITY SYSTEMS FOR BMT IN LMIES
Centres that are currently accredited, inspected or have applied
for JACIE accreditation are overwhelmingly in high-income
economies in Europe. In addition, those economies usually have
other regulatory frameworks within which transplant care is
delivered. For many LMIEs, BMT is a prohibitively expensive and
complex therapeutic strategy, and sometimes only delivered
through private providers, with little or no access to care for the
general population. Despite this, transplant activity is increasing
outside the high-income economies10 in part due to initiatives by
the local medical community to adapt established medical
practice to their own context including economic constraints.18
It is therefore important that quality improvement and accredita-
tion is not inhibitory to the development of BMT in LMIEs.
Through its expanding global network, the EBMT has increasing
contact with transplant professionals in LMIEs who have expressed
high levels of interest in implementing the FACT–JACIE standards
in their units but see the process as organisationally and
economically challenging. In response, JACIE has been developing
a stepped process based on minimum standards to certify quality-
assured BMT services particularly where they are provided to the
broader population through public or not-for-proﬁt healthcare
providers.
The process is based not on inventing new standards, but
instead on a selection of the existing FACT–JACIE standards,
particularly those pertaining to quality management, policies and
procedures (sections B/C/D 4 and 5 of the standards). In principle,
most of these selected standards demand neither major ﬁnancial
investments in technology nor infrastucture, but are more
focussed on driving pragmatic changes in working practices and
implementing the culture of quality improvement. This model
referred to as ‘First-Step’ aims to ensure that centres establish
quality management systems for critical processes as a spring-
board to eventually meeting the more advanced requirements of
the standards.
Challenges remain. The feasibility of this approach has yet to be
tested on the ground, and inevitably various assumptions will
need revisiting after the ﬁrst inspections against the graded
standards. Economic issues will also remain and investment in
quality systems may lose out when more immediate medical care
needs are pressing. To sustain this approach long-term, there will
be a need to recruit inspectors locally along with encouraging
engagement by the local medical communities and a need for
national leaders to advance the model in the future. At least
initially, it is expected that there will be a continued dependence
on experienced inspectors from Europe and elsewhere to perform
the visits, with inspections in the local languages always where
possible, until the local inspector cohort is sufﬁciently experienced
to fully take on the task.
Through this stepped model, the EBMT aims to provide an
internationally validated, entry-level certiﬁcation process with
minimised costs. It is hoped that such an initiative, especially if
allied to increasing EBMT educational and registry activities, will
have a direct impact on patient and donor care, clinical practice
and survival outcomes in LMIE centres.
CONCLUSIONS
The potential for quality and external accreditation standards to
drive clinical improvement is increasingly described in a number
of specialities.19,20 Evidence indicates that success is in part related
to ownership by the clinical community.21 For BMT, this has been
achieved through the EBMT initiating, developing and promoting
JACIE across many countries. JACIE accreditation status now ranks
with centre activity and experience as key factors related to
survival outcomes within any country.22
Despite initial concerns that clinical quality standards and
accreditation might just be a demanding paper exercise with
signiﬁcant costs and limited beneﬁts,23,24 the relatively unim-
peded adoption of JACIE by BMT programmes in countries with
widely differing health services, regulations, laws, cultures and
languages, with data now available to support improvement in
clinical outcomes, is testament to the success of this international
approach.
The success of JACIE is an excellent example for clinical quality
and accreditation systems in other specialities. A number of
potential factors stand out: the early acceptance by some BMT
opinion leaders of the need for quality, international professional
society support;25 the early realisation at local level of the
organisational impact26 and incorporation into national regulatory
requirements. Once acceptance of, and trust in, a system is
established, the more controversial aspects, such as standardised
performance benchmarking of survival outcomes and minimal
centre activity, can be presented as further means of quality
improvement.27–29
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KEY MESSAGES
● Led by front-line BMT professionals for the BMT community.
● Internationally agreed standards supported by the EBMT and
other professional organisations across Europe and beyond.
● Complements and traverses national regulatory, legal, cultural
and language boundaries. A large pool of international
non-remunerated volunteer inspectors overseen by a govern-
ance structure avoids local conﬂicts of interest and makes peer-
review more feasible in smaller countries.
● Promotes a positive interaction among different professionals
involved in the transplant process, from the laboratory to the
bedside.
● Provides standardisation for registry-based analysis of real-
world clinical outcome data, enabling benchmarking and future
development of complex treatment strategies.
● Potential for adaptation to provide a ‘ﬁrst-step’ access to
centres in low- and middle-income countries, while not
compromising original mission for implementing high-quality
standards irrespective of economic factors.
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